Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Neurology
•
Neuro-immunology
Would you consider anti-CD20 agents for treatment of multiple sclerosis in patients with history of breast cancer?
Related Questions
Do you consider steroid-sparing agents for treatment of patients with steroid responsive relapsed Hashimoto Encephalopathy?
What is your approach to immune management in opsoclonus-myoclonus-ataxia syndrome?
Are there any precautions that should be taken when transitioning a patient with multiple sclerosis from one disease modifying therapy to another?
How would you approach the decision to escalate DMT in a patient with relapsing multiple sclerosis who has two to three new T2 lesion but no clinical symptoms?
Would you proceed with anti-CD20 treatment in an MS patient who is VZV IgG negative in spite of vaccination in the last year?
What are potential pitfalls in the use of OCT to support a diagnosis of multiple sclerosis?
What is your treatment approach to neuropsychiatric symptoms secondary to lupus?
When do you start cyclophosphamide for the treatment of anti-NMDA receptor encephalitis?
What is your initial treatment paradigm for someone with both CNS and peripheral neurologic Sjogren’s?
What are the possible or expected MRI findings or changes in progressive MS?
